{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:14:06Z","timestamp":1763774046718,"version":"3.45.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004600","name":"Kyungpook National University Hospital","doi-asserted-by":"publisher","award":["2025-06-005"],"award-info":[{"award-number":["2025-06-005"]}],"id":[{"id":"10.13039\/501100004600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T06:56:40Z","timestamp":1757401000000},"page":"e1160-e1172.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4446-1549","authenticated-orcid":false,"given":"Dong Won","family":"Baek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ik-Chan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-7310","authenticated-orcid":false,"given":"Jeong Suk","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-2067","authenticated-orcid":false,"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Sun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2025.09.004_bib0001","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"L\u00f6ffler","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.09.004_bib0002","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.clml.2025.09.004_bib0004","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.09.004_bib0005","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.23919","article-title":"Outcome of adults with acute lymphocytic leukemia after second salvage therapy","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.clml.2025.09.004_bib0006","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.09.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231201454","article-title":"Survival outcomes in patients with relapsed\/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab","volume":"14","author":"Kantarjian","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0008","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.09.004_bib0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.09.004_bib0010","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2025.09.004_bib0011","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"386","author":"Fo\u00e0","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0012","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2009.1.371","article-title":"Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"2009","author":"Ottmann","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.clml.2025.09.004_bib0013","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.2015.124016","article-title":"Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia","volume":"100","author":"Leoni","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2025.09.004_bib0014","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ajh.21615","article-title":"Dasatinib 140 mg once daily versus 70 mg twice daily in patients with ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study","volume":"85","author":"Lilly","year":"2010","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.clml.2025.09.004_bib0015","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.09.004_bib0016","first-page":"243","article-title":"Resistant mutations in CML and Ph(+)ALL - role of ponatinib","volume":"8","author":"Miller","year":"2014","journal-title":"Biologics"},{"issue":"6","key":"10.1016\/j.clml.2025.09.004_bib0017","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.09.004_bib0018","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin oncol"},{"key":"10.1016\/j.clml.2025.09.004_bib0019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-022-00766-7","article-title":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study","volume":"13","author":"Boissel","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2025.09.004_bib0021","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41409-021-01279-w","article-title":"Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0022","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","article-title":"Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party","volume":"98","author":"Jung","year":"2019","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.004_bib0023","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"issue":"10230","key":"10.1016\/j.clml.2025.09.004_bib0024","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.clml.2025.09.004_bib0025","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.004_bib0026","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.blre.2018.03.006","article-title":"Time to repeal and replace response criteria for acute myeloid leukemia?","volume":"32","author":"Bloomfield","year":"2018","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.clml.2025.09.004_bib0027","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood.2021012328","article-title":"Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium","volume":"139","author":"Buchmann","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.09.004_bib0028","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.09.004_bib0029","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2025.09.004_bib0030","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clml.2025.09.004_bib0031","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/s41375-024-02403-7","article-title":"Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia","volume":"38","author":"van der Ham","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0032","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0033","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/0008-5472.BCD-19-0041","article-title":"Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia","volume":"1","author":"Waanders","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95109-0","article-title":"Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia","volume":"11","author":"Sayyab","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2025.09.004_bib0035","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/EDBK_199505","article-title":"Incorporating immunotherapy into the treatment strategies of B-cell adult acute lymphoblastic leukemia: the role of blinatumomab and inotuzumab ozogamicin","volume":"38","author":"Kantarjian","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.clml.2025.09.004_bib0036","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/ejh.14405","article-title":"Therapeutic strategies for relapsed or refractory B-cell acute lymphoblastic leukemia in adult patients: optimizing the use of monoclonal antibodies","volume":"114","author":"Bruzzese","year":"2025","journal-title":"Eur J Haematol"},{"issue":"18","key":"10.1016\/j.clml.2025.09.004_bib0037","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.3390\/cancers15184623","article-title":"Blinatumomab and inotuzumab ozogamicin sequential use for the treatment of relapsed\/refractory acute lymphoblastic leukemia: a real-life campus all study","volume":"15","author":"Fracchiolla","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clml.2025.09.004_bib0038","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.clml.2025.09.004_bib0039","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1002\/cncr.32335","article-title":"Transplantation in adults with relapsed\/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2025.09.004_bib0040","doi-asserted-by":"crossref","first-page":"520.e1","DOI":"10.1016\/j.jtct.2024.03.004","article-title":"Pretransplant blinatumomab improves outcomes in B cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation","volume":"30","author":"Sayyed","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2025.09.004_bib0041","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41409-021-01279-w","article-title":"Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.clml.2025.09.004_bib0042","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bbmt.2020.01.029","article-title":"Outcomes of allogeneic hematopoietic cell transplantation after salvage therapy with blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"26","author":"Salhotra","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.clml.2025.09.004_bib0043","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.33298","article-title":"Long-term survival of patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"127","author":"Topp","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2025.09.004_bib0044","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","article-title":"TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL","volume":"9","author":"Aldoss","year":"2025","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:10:08Z","timestamp":1763773808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025028940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025028940"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}